QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:WVE

Wave Life Sciences - WVE Stock Forecast, Price & News

$2.45
0.00 (0.00%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.38
$2.53
50-Day Range
$1.28
$4.28
52-Week Range
$1.16
$6.64
Volume
165,772 shs
Average Volume
430,818 shs
Market Capitalization
$150.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Wave Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.5% Upside
$8.00 Price Target
Short Interest
Healthy
3.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.29mentions of Wave Life Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$20.38 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($1.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

35th out of 1,098 stocks

Pharmaceutical Preparations Industry

10th out of 536 stocks

WVE stock logo

About Wave Life Sciences (NASDAQ:WVE) Stock

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Stock Performance

Wave Life Sciences stock opened at $2.45 on Tuesday. The company has a 50 day moving average price of $2.75 and a 200-day moving average price of $2.34. Wave Life Sciences has a fifty-two week low of $1.16 and a fifty-two week high of $6.64. The company has a market capitalization of $150.06 million, a PE ratio of -1.15 and a beta of -0.51.

Wave Life Sciences (NASDAQ:WVE - Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Wave Life Sciences had a negative net margin of 275.31% and a negative return on equity of 558.73%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $3.75 million. On average, analysts forecast that Wave Life Sciences will post -2.01 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of Wave Life Sciences from $10.00 to $8.00 in a research note on Friday, May 13th.

Insider Activity

In related news, Director Ra Capital Management, L.P. purchased 9,480,052 shares of the firm's stock in a transaction dated Thursday, June 16th. The stock was purchased at an average price of $2.15 per share, with a total value of $20,382,111.80. Following the completion of the purchase, the director now owns 17,202,009 shares of the company's stock, valued at approximately $36,984,319.35. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 32.20% of the company's stock.

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Stock News Headlines

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
Wave Life Sciences to raise $70M in stock offering
WAVE Life Sciences Earnings Preview
Wave Life Sciences Q1 2022 Earnings Preview
Wave Life Sciences to Present at Stifel 2022 CNS Days
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
Employees
235
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+226.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-122,250,000.00
Net Margins
-275.31%
Pretax Margin
-275.79%

Debt

Sales & Book Value

Annual Sales
$40.96 million
Book Value
$0.55 per share

Miscellaneous

Free Float
41,527,000
Market Cap
$150.06 million
Optionable
Optionable
Beta
-0.51

Key Executives

  • Dr. Paul B. Bolno M.B.A. (Age 48)
    M.D., MBA, Pres, CEO & Director
    Comp: $994.61k
  • Dr. Chandra Vargeese Ph.D. (Age 61)
    CTO & Head of Platform Discovery Sciences
    Comp: $656.06k
  • Dr. Michael A. Panzara M.D. (Age 55)
    M.P.H., MPH, Chief Medical Officer and Head of Therapeutics Discovery & Devel.
    Comp: $692.94k
  • Mr. Kyle B. Moran CFA (Age 51)
    CFO & Principal Accounting Officer
  • Kate Rausch
    Head of Investor Relations
  • Ms. Linda Rockett J.D.
    Gen. Counsel
  • Ms. Anne-Marie Li-Kwai-Cheung
    Sr. VP of Regulatory Affairs, Compliance & Policy
  • Dr. Christopher Francis Ph.D. (Age 44)
    Sr. VP of Corp. Devel. & Head of Emerging Areas
  • Mr. Jonathan Rosin
    Chief HR Officer
  • Dr. Sridhar Vaddeboina Ph.D.
    Sr. VP of Chemistry, Manufacturing & Controls













WVE Stock - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" WVE shares.
View WVE analyst ratings
or view top-rated stocks.

What is Wave Life Sciences' stock price forecast for 2022?

1 Wall Street analysts have issued 1 year price targets for Wave Life Sciences' shares. Their WVE share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 230.6% from the stock's current price.
View analysts price targets for WVE
or view top-rated stocks among Wall Street analysts.

How has Wave Life Sciences' stock price performed in 2022?

Wave Life Sciences' stock was trading at $3.14 at the beginning of the year. Since then, WVE shares have decreased by 22.9% and is now trading at $2.42.
View the best growth stocks for 2022 here
.

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our WVE earnings forecast
.

How can I listen to Wave Life Sciences' earnings call?

Wave Life Sciences will be holding an earnings conference call on Thursday, August 11th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) announced its quarterly earnings data on Thursday, May, 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.06. The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.75 million. Wave Life Sciences had a negative net margin of 275.31% and a negative trailing twelve-month return on equity of 558.73%.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Y Intercept Hong Kong Ltd (0.02%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Kyle Moran, Michael A Panzara, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $2.42.

How much money does Wave Life Sciences make?

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $148.23 million and generates $40.96 million in revenue each year. The company earns $-122,250,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How many employees does Wave Life Sciences have?

Wave Life Sciences employs 235 workers across the globe.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.

This page (NASDAQ:WVE) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.